Javascript must be enabled to continue!
Yttrium oxide nanoparticles induce selective cytotoxicity, genomic instability and ROS mitochondrial P53 mediated apoptosis in human pancreatic cancer cells
View through CrossRef
Abstract
Pancreatic cancer is a hard-to-treat tumor with a poor prognosis. While traditional pancreatic cancer therapies can be effective, issues like cytotoxicity, low selectivity, and drug resistance still pose major challenges. Nanotechnology has shown promise in improving cancer diagnosis and treatment. Yttrium oxide nanoparticles (Y2O3-NPs), for example, have demonstrated potent selective cytotoxicity against triple negative breast cancer cells; but their effects on pancreatic cancer cells have not been explored. This study aimed to explore the impact of Y2O3-NPs on cell proliferation, DNA integrity, and oxidative stress in pancreatic cancer (PANC-1) and human skin fibroblast (HSF) cells. The cytotoxicity of Y2O3-NPs after 72 h were estimated using Sulforhodamine (SRB) cytotoxicity assay, while alkaline Comet assay was done to study genomic DNA integrity. Generation level of reactive oxygen species (ROS) and integrity of mitochondrial membrane potential were also analyzed. Apoptosis induction was investigated using Flow Cytometry and expression level of apoptotic (p53), anti-apoptotic (Bcl2) and mitochondrial (ND3) genes was measured using quantitative RTPCR. Our findings exhibited that Y2O3-NPs had strong selective cytotoxicity against PANC-1 cells with an IC50 value of 31.06 µg/ml, while having minimal effect on normal HSF cells (IC50 = 319.21 µg/ml). Treatment of PANC-1 cells with Y2O3-NPs at the IC50 concentration for 72 h significantly increased intracellular ROS levels and DNA damage, along with a notable reduction in mitochondrial membrane potential. Additionally, a significant rise in necrotic, early, and late apoptotic cells was observed, accompanied by downregulation of the anti-apoptotic Bcl2 gene and upregulation of the apoptotic p53 and mitochondrial ND3 genes. These findings highlight the selective toxicity of Y2O3-NPs towards cancerous PANC-1 cells, with minimal impact on normal cells. Y2O3-NPs appear to induce apoptosis in cancer cells by increasing ROS generation, damaging DNA, disrupting mitochondrial function, and triggering cell death. This study suggests that Y2O3-NPs may be a promising candidate for pancreatic cancer treatment. Further research is needed to fully explore their therapeutic potential.
Springer Science and Business Media LLC
Title: Yttrium oxide nanoparticles induce selective cytotoxicity, genomic instability and ROS mitochondrial P53 mediated apoptosis in human pancreatic cancer cells
Description:
Abstract
Pancreatic cancer is a hard-to-treat tumor with a poor prognosis.
While traditional pancreatic cancer therapies can be effective, issues like cytotoxicity, low selectivity, and drug resistance still pose major challenges.
Nanotechnology has shown promise in improving cancer diagnosis and treatment.
Yttrium oxide nanoparticles (Y2O3-NPs), for example, have demonstrated potent selective cytotoxicity against triple negative breast cancer cells; but their effects on pancreatic cancer cells have not been explored.
This study aimed to explore the impact of Y2O3-NPs on cell proliferation, DNA integrity, and oxidative stress in pancreatic cancer (PANC-1) and human skin fibroblast (HSF) cells.
The cytotoxicity of Y2O3-NPs after 72 h were estimated using Sulforhodamine (SRB) cytotoxicity assay, while alkaline Comet assay was done to study genomic DNA integrity.
Generation level of reactive oxygen species (ROS) and integrity of mitochondrial membrane potential were also analyzed.
Apoptosis induction was investigated using Flow Cytometry and expression level of apoptotic (p53), anti-apoptotic (Bcl2) and mitochondrial (ND3) genes was measured using quantitative RTPCR.
Our findings exhibited that Y2O3-NPs had strong selective cytotoxicity against PANC-1 cells with an IC50 value of 31.
06 µg/ml, while having minimal effect on normal HSF cells (IC50 = 319.
21 µg/ml).
Treatment of PANC-1 cells with Y2O3-NPs at the IC50 concentration for 72 h significantly increased intracellular ROS levels and DNA damage, along with a notable reduction in mitochondrial membrane potential.
Additionally, a significant rise in necrotic, early, and late apoptotic cells was observed, accompanied by downregulation of the anti-apoptotic Bcl2 gene and upregulation of the apoptotic p53 and mitochondrial ND3 genes.
These findings highlight the selective toxicity of Y2O3-NPs towards cancerous PANC-1 cells, with minimal impact on normal cells.
Y2O3-NPs appear to induce apoptosis in cancer cells by increasing ROS generation, damaging DNA, disrupting mitochondrial function, and triggering cell death.
This study suggests that Y2O3-NPs may be a promising candidate for pancreatic cancer treatment.
Further research is needed to fully explore their therapeutic potential.
Related Results
Abstract 3500: Mitochondrially targeted p53 domains as a stand alone or adjunct to paclitaxel for the treatment of ovarian cancer
Abstract 3500: Mitochondrially targeted p53 domains as a stand alone or adjunct to paclitaxel for the treatment of ovarian cancer
Abstract
Although the main function of p53 is a nuclear transcription factor that has important roles in cell cycle arrest, DNA repair, and apoptosis, p53 can direct...
Abstract 599: Id4 acts as a tumor suppressor by inducing apoptosis and senescence in p53-dependent manner
Abstract 599: Id4 acts as a tumor suppressor by inducing apoptosis and senescence in p53-dependent manner
Abstract
The physiological mechanisms that can restore biological activity of mutant p53 is an area of high interest given that mutant p53 expression is observed in ...
Abstract 1706: Investigating the interaction between ETS family members and mutant p53
Abstract 1706: Investigating the interaction between ETS family members and mutant p53
Abstract
Cancer cases are on the rise globally requiring a deeper understanding of the disease and identification of novel therapeutic targets. Mutations in genes of...
Abstract 422: Novel approach to destabilization of oncogenic mutant p53 and therapeutic implications
Abstract 422: Novel approach to destabilization of oncogenic mutant p53 and therapeutic implications
Abstract
Introduction: Mutant p53 drives several hallmarks of cancer through a gain-of-function oncogenic program. The oncogenicity of mutant p53 includes sustained ...
High P53 Protein Expression Level Independent of Mutational Status Is An Adverse Prognostic Factor for Survival in Acute Myeloid Leukemia
High P53 Protein Expression Level Independent of Mutational Status Is An Adverse Prognostic Factor for Survival in Acute Myeloid Leukemia
Abstract
Abstract 1490
Background:
The tumor suppressor p53 is frequently mutated in human cancer, including acut...
Revision of the genus Aspicera Dahlbom, 1842 (Hym.: Figitidae: Aspicerinae)
Revision of the genus Aspicera Dahlbom, 1842 (Hym.: Figitidae: Aspicerinae)
The genus Aspicera Dahlbom (Hymenoptera: Cynipoidea: Figitidae: Aspicerinae) is revised herein. Aspicera has a Holarctic distribution, being here cited for the first time from the ...
The Complex Interplay Between p53 and Aneuploidy in Cancer
The Complex Interplay Between p53 and Aneuploidy in Cancer
In this thesis, we dived into the complex relationship between p53 and aneuploidy. p53 acts as a central tumor suppressor that responds to diverse cellular stresses, including DNA ...
Jun Dimerization Protein 2 (JDP2) Increases p53 Transactivation by Decreasing MDM2
Jun Dimerization Protein 2 (JDP2) Increases p53 Transactivation by Decreasing MDM2
The AP-1 protein complex primarily consists of several proteins from the c-Fos, c-Jun, activating transcription factor (ATF), and Jun dimerization protein (JDP) families. JDP2 has ...

